Phase 1 trial assesses whether fecal microbiota transplant impacts cancer patients resistant to immu

December 10, 2020

In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes. Their results - which show a positive response in three out of the ten patients analyzed - are reported from a Phase 1 clinical trial. Though noting some limitations of their work, the authors say their findings support the concept of overcoming resistance to immunotherapy by modulating the gut microbiota. Many cancer patients who receive PD-1 blockade therapy do not respond to it, developing resistance. Among the most promising routes for overcoming resistance to anti-PD-1 therapy is altering the gut microbiome, which has been shown to influence the response of tumors to anti-PD-1 immunotherapy in pre-clinical mouse models and observational patient cohorts. While no specific bacterial taxa have been consistently associated with this response, fecal microbiota transplantation (FMT) - which transfers the entire gut microbiota from one host to another - has demonstrated promising results in pre-clinical models. Based on this data, Erez N. Baruch and colleagues designed a Phase 1 clinical test to evaluate how FMT, followed by re-initiation of anti-PD-1 immunotherapy, affected ten patients with metastatic melanoma who'd previously grown resistant to anti-PD-1 treatment. The transplant material was from one of two melanoma patients ("Donor 1" or "Donor 2"), both of whom had responded positively to anti-PD-1 therapy for at least one year. After receiving FMT from Donor 1 or Donor 2, three out of ten patients responded to subsequent anti-PD-1 treatment, as defined by regression of tumor size. All three had received their FMT from Donor 1, the authors note. The reason for the positive response as derived from Donor 1 alone is not clear, they say, as the study was statistically powered to assess safety and not to compare efficiency between donors. Even as the results offer no clear association between specific taxa and clinical response to FMT, however, they point to the combination of FMT and re-induction of anti-PD-1 therapy being "safe, feasible and potentially effective," say Baruch and colleagues.

American Association for the Advancement of Science

Related Immunotherapy Articles from Brightsurf:

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Taking the itch out of cancer immunotherapy
Researchers from the University of Tsukuba have determined that PD-1 expression on CD8 T cells is the biological pathway that leads to psoriasis-like dermatitis, an unfavorable side effect of cancer immunotherapy with PD-1 inhibitors.

Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

New immunotherapy to beat cancer
Sophie Lucas (University of Louvain de Duve Institute) and her team succeeded in neutralising a molecule that blocks the immune system against cancer.

New hydrogels for T-cell growth to be used in cancer immunotherapy
A team with the participation of researchers from the Spanish National Research Council (CSIC) has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A blood test could predict who benefits from immunotherapy
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Immunotherapy safe for patients with COVID-19, cancer
Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

A helping hand for cancer immunotherapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

Read More: Immunotherapy News and Immunotherapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to